Business & Industry
Business & Industry
Cold Chain and Temperature-Controlled Laboratory Equipment in Pharmaceutical Research and Development
Temperature-sensitive biologics, advanced therapeutics, and pharmaceutical research materials demand specialized cold storage infrastructure spanning ultra-low temperature freezers, controlled-rate freezing systems, and validated stability chambers that maintain precise thermal conditions throughout research, development and testing workflows.
Business & Industry
CMS Unveils a New Voluntary Access Programme For GLP-1
In the most recent of a string of announcements ahead of the holiday season, Centers for Medicare & Medicaid Services (CMS) has unveiled a new voluntary access programme which aims to widen the usage of GLP-1 agonist medicines when it...
Business & Industry
Bevacizumab to be Used by NHS for Colorectal Cancer
NICE has gone ahead and cleared the way for bevacizumab to be used by NHS in order to treat colorectal cancer for the very first time, all thanks to the availability when it comes to the lower-cost biosimilar versions...
Business & Industry
Sanofi to Buy Vaccine Developer Dynavax in a $2.5b Deal
The French pharma giant, Sanofi, has started a $15.50 per share cash tender offer when it comes to Emeryville, California-based vaccine developer Dynavax, which already goes on to market an adult vaccine that protects against the hepatitis B virus...
Business & Industry
Laboratory Automation and Robotics: Improving Accuracy and Throughput in Pharma R&D
Laboratory automation and robotics are redefining pharmaceutical R&D by eliminating manual errors, enabling high-throughput screening, and freeing scientists to focus on innovation through "lights-out" operations.
Business & Industry
Continuous Manufacturing Equipment: Adoption Barriers and Industry Readiness
While continuous manufacturing offers efficiency and quality benefits, high capital costs and technical barriers like PAT integration, feeder accuracy, and RTD modeling slow its widespread adoption in pharma.
BioPharma
AstraZeneca Commits $100mn for Pan-KRAS Inhibitor by Jacobio
AstraZeneca has gone ahead and committed $100 million to head deeper into the KRAS space by way of securing the right when it comes to a clinical-stage, multitarget asset from Jacobio Pharma of China.
The U.K.-based pharma giant has scored...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read















